Kornimate/medical-research-clean huggingface dataset:
optimization of chest tube drainage management

Conditions: Lung Diseases; Age >18 Years-old; Patient Who Received Thoracoscope Surgery

Summary: early recovery after surgery was new developing science in recent years. however , there was few reports in thoracic surgery field . investigators try to using digital chest drainage management system into the field of postoperative care and to see whether it could help patients to recovery from surgery as soon as possible. according to investigators's clinical data collecting , investigators will establish a new postoperative care guideline for those patients who receive thoracic surgery

drainage of the space between the ribs and lungs has been practiced since the time of hippocrates. thus far, the function of chest tubes, specifically to drain fluid or air from the pleural space, has virtually remained unchanged for more than 3000 years. the use of chest drainage tubes after thoracic surgery is crucial to evacuate air leakage and/or pleural effusion; however, delayed tube removal may exacerbate pain, delay recovery of lung function and prolong hospitalization. recently, thopaz digitally monitored thoracic drainage system (medela healthcare, baar, switzerland)has been designed to provide objective measurements of air leakage and pleural pressure. with this system, air leakage and pleural pressure can be accurately measured in ml/min and mm h2o, respectively. the rate of air leakage can be seen on a display in real time. digital surveillance for air leakage is reported to reduce interobserver disagreement in decision making in the management of patients with chest tubes, which might help caregiver a more solid evidence of strategies of postoperative chest drainage care.

Eligibility criteria:
inclusion criteria: * volunteer to join the study after thoroughly explanations * patient who received thoracoscope surgery for lung lesion exclusion criteria: * not willing to join the study after thoroughly explanations * patients who have not received thoracoscope surgery for lung lesion

Keywords: digital chest tube system, shorten hospital stay
efficacy and tolerance of flucortac in patients with orthostatic neurogenic hypotension

Conditions: Neurogenic Orthostatic Hypotension

Summary: to evaluate the efficacy of a 4-week fludrocortisone (flu) treatment on systolic blood pressure depression after 5 minutes of active orthostatism in patients with neurogenic orthostatic hypotension (hon) symptomatic, despite treatment with non-drug measures with or without midodrine.

the objective of the study is to demonstrate the efficacy of flu on systolic blood pressure depression in patients with neurogenic orthostatic hypotension. the study is randomised versus placebo.each patient will be followed for a maximum of 5 months, with no more than 8 visits to the investigator (v0 at day-7, v1 at d0, v2 at d7, v3 at d+14, v4 at d+21, v5 at d+ 28, v6 at d+56 and v7 only for patients on the flu arm at d+140. the presence of a comparator control group with placebo permits to evaluate the efficacy and the tolerance of flu independently of the natural evolution of the pathology, in patients benefiting from a non-drug or possibly medicated treatment (midodrine) but insufficient.

Eligibility criteria:
inclusion criteria: * diagnosis of orthostatic hypotension (ho), ie a blood pressure drop\> 20 and / or 10 mmhg within 3 minutes after active and symptomatic lifting * patient suffering from a neurological disease * orthostatic neurogenic hypotension persistent and symptomatic despite non-drug measures exclusion criteria: * hypersensitivity to flu or any of its excipients * non orthostatic neurogenic hypotension * history of proven heart failure * history of left ventricular systolic dysfunction * uncompensated hypokalemia * patient with poorly balanced grade 3 hypertension * pregnant patient at the time of inclusion * nursing patient
study of the closed-loop treatment concept of atrial fibrillation in the atrial fibrillation population

Conditions: Atrial Fibrillation

Summary: this study aims to evaluate the concept of closed-loop treatment of atrial fibrillation for the optimization of the treatment strategy.

this study aims to evaluate the concept of closed-loop treatment of atrial fibrillation for the optimization of the treatment strategy, the improvement of disease outcome and the economic value of the atrial fibrillation population in the northern shanghai community. improve the disease cognition of patients with atrial fibrillation, and promote the development of the concept of closed-loop treatment of atrial fibrillation.

Eligibility criteria:
inclusion criteria: * atrial fibrillation patients；ability to act autonomously, understand and sign informed consent； exclusion criteria: * none（all patients with atrial fibrillation were enrolled in this study indiscriminately and followed up）

Keywords: atrial fibrillation；closed-loop treatment；
proof of concept in patients with generalized anxiety disorder (gad)azd7325

Conditions: Anxiety Disorders

Summary: the purpose of this research study is to determine whether astrazeneca's drug azd7325 is safe and effective in the treatment of generalized anxiety disorder.


Eligibility criteria:
inclusion criteria: * signed informed consent before any study-related procedures start. * the patient is previously diagnosed with generalized anxiety disorder. * the patient has a hads-a (anxiety) score ≥10 at both screening and randomization. exclusion criteria: * patient has a lifetime history of schizophrenia or other psychotic disorders * patient has a history of seizures or seizure disorder. * patient is pregnant or breast feeding. * patient has received electroconvulsive treatment (ect) in the past.

Keywords: generalized anxiety disorder gad anxiety
biomechanical effects of three types of foot orthoses in individuals with posterior tibialis tendon dysfunction

Conditions: Posterior Tibial Tendon Dysfunction

Summary: background : posterior tibialis tendon dysfunction (pttd) is characterized by a loss of function of the muscle caused by the degeneration of the tendon leading to a flattening of the arch. fos can be used as a treatment option, but their biomechanical effects are not yet fully understood. the aim of this study was to investigate the effects of three different types of foot orthoses (fos) on gait biomechanics in individuals suffering from pttd. methods : fourteen individuals were recruited with painful stage 1 or 2 pttd based on the johnson and strom's classification. quantitative gait analysis of the affected limb was performed in four conditions: shoed condition (shoe), prefabricated fos condition (pfo), neutral custom fos condition (cfo) and five degrees varus (medial wedge) with a 4 mm medial heel skive custom fos condition (cvfo). a curve analysis, using 1d statistical parametric mapping (smp), was used to assess differences in lower limb joint motion, joint moments and muscle activity over the stance phase of gait across conditions.


Eligibility criteria:
inclusion criteria: * symptoms located to the medial ankle or foot pain on palpation to the posterior tibialis muscle tendon positive single or double heel-rise test foot flattening and ''too many toes" sign exclusion criteria: * rigidity of those deformities pain on palpation of the peroneal muscles wearing any type of foot and/or ankle orthoses one month prior to the study onset history of corticosteroid injection in the tendon one month prior to the study onset having a neurological disease or past history of surgery to the affected ankle

Keywords: posterior tibialis tendon dysfunction, foot orthoses,
development of a robust and reliable pulse oximeter for children with pneumonia in low-income countries

Conditions: Pneumonia in Children; Measurement of Peripheral Oxygen Saturation

Summary: this study is to test the usability of a new pulse oximeter probe designed for children 0-5 years.

pneumonia is the leading infectious cause of death in children under five. world health organization guidelines recommend measurement of peripheral oxygen saturation (spo2) in children with pneumonia to guide treatment. this project focuses on the design of a new 'lifebox' pulse oximeter probe for use in children 0-5 years of age. a new oximeter probe compatible with the lifebox oximeter has been designed to be used for children 0-5 years in all settings. the aims of the study are to: 1. to evaluate the usability of the redesigned lifebox oximeter probe by an expert user 2. to evaluate the usability of the redesigned oximeter probe by trained healthcare workers, against defined product specifications. 3. to compare the usability of the redesigned oximeter probe to a market leading probe

Eligibility criteria:
inclusion criteria: patient participants: * inpatients (or child awaiting surgery on pre-operative ward) in great ormond street hospital, or government facilities in malawi and bangladesh * aged 0 - 59 months * clinically stable (as judged by the ward sister and medical team) * parent (or adult with parental responsibility) present * informed consent from the parent (or adult with parental responsibility) healthcare worker participants: * nursing staff employed at great ormond street hospital who are trained in the use of pulse oximetry or government healthcare providers working in malawi and bangladesh * written informed consent from the healthcare worker exclusion criteria: patient participants: * unstable or critically unwell patients (as judged by their medical team) * parents (or adult with parental responsibility) who are not able or willing to give informed consent * parents (or adult with parental responsibility) unable to speak english well enough to understand study methods or consent form (uk only) * for part of the study assessing usability of the probe by healthcare workers, patients with oxygen saturation 95% or below will be excluded healthcare worker participants: * healthcare providers who are not trained to use a pulse oximeter * healthcare providers who have not given written informed consent

Keywords: pulse oximetry children
validation and reproducibility of s.p.a.t. with allergens

Conditions: Allergy to House Dust; Allergy Pollen

Summary: to improve accuracy and take out human error opportunities, hippo dx developed s.p.a.t., an automated skin prick test. this study will provide a comparison between manual and automated skin prick test in allergic and non-allergic individuals with a panel of common inhalant allergens. the primary endpoint is to compare the accuracy of s.p.a.t. to detect sensitization to common aeroallergens compared to a manual skin prick test (spt). it is a prospective monocentric study that will include 120 study participants.


Eligibility criteria:
inclusion criteria: adults (18-65y) with presence or absence of self-reported symptoms of inhalant allergy will be included. exclusion criteria: * skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment * use of antihistaminic medication \< 7 days before the start of the study * use of tricyclic antidepressants (antihistamine activity) \< 7 days before the start of the study * use of topical corticoids on the forearm \< 7 days before the start of the study * use of omalizumab \< 6 months before the start of the study * pregnancy: there is a remote possibility of inducing a systemic allergic reaction that could induce uterine contractions or necessitate the use of epinephrine (thought to cause constriction of the umbilical artery)
a study assessing kb407 for the treatment of cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study will evaluate safety and tolerability of ascending doses of nebulized kb407 in adults with cystic fibrosis.


Eligibility criteria:
inclusion criteria: 1. the subject must have read, understood, and signed an institutional review board/ethics committee (irb/iec) approved informed consent form and must be able to and willing to follow study procedures and instructions 2. subjects aged 18 years or older at the time of informed consent 3. a confirmed diagnosis of cf as defined by clinical signs and symptoms of cf and at least one of the following: * a historical sweat chloride value \>60 mmol/l * two copies of a disease causing mutation in the cftr gene 4. clinically stable in the opinion of the investigator 5. percent predicted fev1 ≥50% and ≤100% of the predicted normal for age, gender, and height at screening 6. resting oxygen saturation ≥92% on room air at screening exclusion criteria: 1. initiation of any new chronic therapy (eg, cftr modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose 2. hospitalization, sinopulmonary infection, cf exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the investigator, may confound study results 3. treatment for burkholderia cenocepacia, burkholderia dolosa, or nontuberculosis mycobacteria infection within 3 months prior to the first dose 4. participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose 5. history of or listed for solid organ transplantation 6. any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of kb407 7. an active oral herpes infection 30 days prior to the first dose 8. has received a vaccine within 72 hours prior to the first dose or has a planned vaccination during the treatment period 9. women who are pregnant or nursing 10. subject who is unwilling to comply with contraception requirements per protocol 11. clinically significant abnormalities of hematology or chemistry testing at screening that the investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment 12. subject has a known hypersensitivity to inhaled glycerol 13. subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the investigator 14. bronchoscopy participants only: unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the investigator
analysis of effectiveness and safety of teclistamab in relapsed and refractory multiple myeloma patients

Conditions: Multiple Myeloma

Summary: 200 adult patients with multiple myeloma receiving teclistamb will be included. effectiveness, safety, and condition of use of teclistamab in early access program (post-ma) will be assessed. primary objective is the evaluation of overall response rate (orr) of teclistamab according to imwg criteria. this is a multicenter, prospective, observational study.


Eligibility criteria:
inclusion criteria: * adult patient (≥18 years) with multiple myeloma who will receive at least one dose of teclistamab (first dose of the step-up dose) exclusion criteria: * patients alive at the start of the study who did not receive study information or who objected to the collection of data * patients who received teclistamab as part of an interventional clinical trial * patients who are initiating teclistamab as part of a current interventional clinical trial

Keywords: teclistamab refractory multiple myeloma real word evidence study
evaluation of breast reduction techniques

Conditions: Breast Reductions

Summary: the purpose of this study is to retrospectively evaluate breast reduction techniques in terms of complications, functionality, patient satisfaction, and cosmetic outcomes.

a breast reduction is a common operation with a fairly high complication rate as large incision techniques require undermined skin flaps to be closed under tension. this study is evaluation the open incision breast reduction technique to a liposuction assisted breast reduction. this study will evaluate these two breast reduction techniques in terms of complication rates, functionality, patient satisfaction, and cosmetic outcomes. participants will be asked to complete the breast-q survey regarding their breast reduction postoperatively.

Eligibility criteria:
inclusion criteria: * patients who underwent a breast reduction between 2013 and 2019 * all patients who underwent a liposuction assisted or layered skin incision pedicled technique breast reduction. exclusion criteria: * patients who underwent additional procedures simultaneously at the time of the breast reduction.

Keywords: breast reductions
lama2 genetic correction

Conditions: MDC1A

Summary: merosin-deficient congenital muscle dystrophy type 1a (mdc1a), or lama2 muscular dystrophy (lama2-md) is a severe autosomal recessive form of muscular dystrophy that is caused by homozygous or compound heterozygous mutations in the laminin alpha 2 (lama-2) gene. many different lama-2 mutations have been reported. in most cases, mdc1a is diagnosed within the first year of life, and is characterized by hypotonia, delayed motor development and white matter abnormalities. currently, no efficient treatment is available for this patient group. generally, mdc1a patients with mutations causing a premature stop codon are most severely affected (early onset lama2-md) and patients with missense mutations are generally affected more mild affected and more late-onset (late onset lama2-md). however, large variation in disease severity and clinical course is observed, even between individuals with the same mutation, e.g. the lama2 c.5562+5g\>c mutation, which is frequently observed in dutch mdc1a patients. this study aims to isolate and culture fibroblasts and myogenic stem cells called mesoangioblasts from the skin and muscle biopsies of adult lama2 mutation carriers to explore if genetic correction of lama2 mutations using crispr-cas9 can be achieved and subsequently assess the effect in vitro, as a first step towards therapy development.


Eligibility criteria:
inclusion criteria: * lama2 mutation carriers: * age \>18 years * heterozygous or homozygous lama2 c.5562+5g\>c mutation * written informed consent controls: * written informed consent * age \>18 years * no muscular dystrophy or other disease known to affect muscle morphology or function exclusion criteria: * mdc1a patients and controls: * no informed consent * use of anti-coagulants, anti-thrombotics and other medication influencing coagulation * have a weekly alcohol intake of ≥ 35 units (men) or ≥ 24 units (women) * current history of drug abuse * a history of strokes * significant concurrent illness * ongoing participation in other clinical trials * major surgery within 4 weeks of the visit * pregnant or lactating women * patients unable and/or unwilling to comply with treatment and study instructions * any other factor that in the opinion of the investigator excludes the patient from the study

Keywords: mdc1a lama2 muscular dystrophy mesoangioblasts
effect of taurine on glycemic control in type i and type ii diabetic patients

Conditions: it is a Group of Metabolic Diseases in; Which a Person Has High Blood Sugar, Either; Because the Body Does Not Produce Enough Insulin,; or Because Cells do Not Respond to the Insulin That; is Produced.

Summary: diabetes mellitus (dm) and its vascular complications are the one of the most prevalent diseases in the state of qatar. it is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy, cardiomyopathy, and severe vascular dysfunction. the complications of diabetes are caused by either insulin deficiency (type 1 dm) or insulin resistance (type ii dm).unfortunately, effective and sustainable prevention programs of diabetes are limited, and treatment options for type ii dm are restricted. current therapy is based upon control of blood glucose, cholesterol and triglycerides, primarily through insulin replacement in type i diabetes or oral hypoglycemic agents and/or insulin replacement in type ii diabetes. new therapies able to prevent vascular complications of diabetes are needed to decrease the occurrence of end organ damage and improve the quality of life of the people. safe and effective nutritional supplements that could be given along with the regular treatment of the patients that might reduce the need for insulin replacement therapy provide tighter glucose control and protect against oxidative stress and the vascular pathology associated with diabetes mellitus are the need of the hour. our hypothesis is that supplementation of taurine in the diets of diabetic patients might reduce the dose or need for insulin replacement therapy and protect them against oxidative stress that is responsible for the complications of diabetes mellitus.


Eligibility criteria:
inclusion criteria: 1. male or female 2. above 18-65 years of old 3. known diabetic patients with hba1c\>8.0% 4. people who provide signed informed consent - exclusion criteria: * 1. pregnancy 2. diabetic patients with hba1c \<8.0 % 3. recent or prospective surgical interventions 4. complications of type i and type ii dm, e.g., active cardiovascular disease, nephropathy, retinopathy, neuropathy 5. people who do not provide signed informed consent

Keywords: taurine,diabetes mellitus,oxidative stress,glycemic control
formulation and food effect study of azd1386 in healthy volunteers

Conditions: Pharmacokinetics

Summary: to investigate the pharmacokinetics of two oral solid formulations of azd1386 in relation to the azd1386 oral solution.


Eligibility criteria:
inclusion criteria: * females must be non-fertile (amenorrhea and no pregnancy in the last 12 months prior to enrolment or documentation of being irreversible surgically sterile). * healthy male volunteers with bmi between 18 and 30 kg/m2 * clinical normal physical findings, including blood pressure, pulse rate above 45 bpm, ecg, and laboratory assessments. * normal qtc interval on baseline ecg, between 360-450 msec, according to the fridericia formula. exclusion criteria: * history of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensitivity as judged by the investigator. * requirement of concomitant medication during the study, excluding hormone replacement therapy (hrt) or use of drugs with enzyme inducing properties with 3 weeks of first dose * smoking more than 7 cigarettes per week or consumption of more than 3 portion of snuff or equivalent per day within 30 days before first administration of study drug * a family history of short qt syndrome (sqts) or sudden cardiac death (scd) amongst first degree relatives and who have a qt/qtc \<360 ms

Keywords: formulation pharmacokinetics